Dynavax Technologies Corporation has received a rejection from the FDA for its Heplisav-B, hepatitis B vaccine. In a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for Heplisav B for immunization of adults 18 years and older against hepatitis B infection.
Attorney Advertising Bronstein, Gewirtz & Grossman, LLC, said that as on November 14, 2016, Dynavax dropped over 62% on intraday trading after Dynavax’s announcement about receiving a Complete Response Letter from the U.S. FDA, requesting additional information “including clarification regarding specific adverse events of special interest (AESIs), a numerical imbalance in a small number of cardiac events in a single study (HBV-23), new analyses of the integrated safety data base across different time periods, and post-marketing commitments.”
The FDA issues CRLs to communicate that the Agency has completed a review cycle of an application and to request additional information for review and approval. Dynavax expects a Class 2 designation for a resubmission of the BLA, which would result in a target review period of six months.
In the CRL, the FDA said that it has not yet completed its review of responses received from Dynavax in early October, including those pertaining to AESIs and the numerical imbalance in cardiac events.
“The responses included an extensive analysis that included independent expert consultation supporting our view that the imbalance was driven by an unexpectedly low number of events in the comparator arm,”the statement from Dynavax said.
The company also commented that it appeared the Agency could not fully assess the responses in the current review period. In the CRL, there is no request for additional clinical trials and there are no apparent concerns with rare serious autoimmune events.
Dynavax seeks meeting with the FDA ASAP
“The CRL is consistent with our opinion that HEPLISAV-B is approvable and we are seeking to meet with the FDA as soon as possible,” said Eddie Gray, chief executive officer of Dynavax. “However, the time and resources that will be required to gain approval leads us to consider that we may not be able to advance this program on our own and we are moving swiftly to identify a potential pharmaceutical or financial partner. We will maintain our efforts on the oncology programs, including our lead cancer immunotherapy candidate, SD-101, for which we recently announced encouraging early clinical data in metastatic melanoma.”